TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ZGJAK002 trial: Efficacy and safety of jaktinib in patients with MF

By Sabina Ray

Share:

Mar 18, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.


Jaktinib, a Janus kinase, and activin A receptor type I inhibitor, is a deuterated form of momelotinib and has shown promising results for treating patients with myelofibrosis (MF), specifically in spleen volume reduction and symptom relief.

Here, we summarize a long-term follow-up of the ZGJAK002 trial (NCT03886415) published by Zhang et al.1 in American Journal of Hematology assessing the safety and efficacy of jaktinib in Chinese patients with intermediate to high-risk MF.

Study design1

  • Phase II, open-label dose comparison trial 30.7 months after trial initiation
  • Patients (N = 118) were assigned 100 mg jaktinib twice daily (BID, n = 66) or 200 mg jaktinib once daily (QD, n = 52)
  • The primary endpoint was the proportion of patients with 35% decrease in spleen volume (SVR35) at Week 24.
  • Secondary endpoints included total symptom score improvement by 50% (TSS50), improvement in anemia, and safety profile.

Key findings1

  • More patients achieved SVR35 with 100 mg BID vs 200 mg QD (Figure 1)
    • The proportion of patients achieving spleen volume reductions increased over time, indicating durable responses
  • TSS50 improvements and hemoglobin levels were sustained in both groups from Week 48 to Week 120 in long-term follow-up results (Table 1).
  • No further safety signals were identified in either cohort, common Grade 3 adverse events outlined in Table 1.

Table 1. Key long-term efficacy and safety data for jaktinib 100 mg BID and 200 mg QD regimens*

AE, adverse event; BID, twice daily; TSS50; total symptom score improvement by 50%; QD, once daily.
*Adapted from Zhang, et al.1

 

100 mg BID (n=66)

200 mg QD (n=52)

TSS50 (%)

              Week 48

81.6

81.5

              Week 120

63.6

81.0

Mean hemoglobin change (g/L)

              Week 48

4.76

8.69

              Week 120

0.25

0.25

Grade 3 AEs (%)

              Anemia

15.2

21.2

              Thrombocytopenia

15.2

11.5

              Infectious pneumonia

10.6

1.9

  • Median overall survival was not met by either cohort, with 36-month survival rates of 78.0% vs 73.6%, respectively
    • Deaths were reported in 18.2% and 25%, respectively

Figure 1. SVR35 in patients with intermediate to high-risk MF treated with 100 mg BID or 200 mg QD jaktinib* 

BID, twice daily; MF, myelofibrosis; QD, once daily; SVR35, spleen volume reduction 35%.
*Adapted from Zhang, et al.1

Key learnings

  • Both 100 mg BID and 200 mg QD regimens of jaktinib demonstrated a sustained improvement in SVR35, anemia, and TSS50. However, a higher proportion of patients achieved SVR35 with 100 mg BID.
  • Along with sustained elevation of hemoglobin levels and consistent safety profile, this long-term data supports further evaluation of 100 mg BID over 200 mg QD in patients with intermediate to high-risk MF who require a rapid spleen response.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content